Milk Thistle (Silymarin): The Number the Label Won't Tell You

Milk Thistle Benefits: Graded by Evidence

Looking for a tested product? See our best milk thistle ranked by disclosed silymarin and cost →

The best-evidenced benefit: lowering elevated liver enzymes

This is where milk thistle's data is strongest. A 2024 systematic review and meta-analysis of 26 randomized controlled trials in 2,375 people with nonalcoholic fatty liver disease found silymarin significantly reduced ALT (standardized mean difference −12.39) and AST (−10.97), along with total cholesterol, LDL, and a fatty-liver index, and improved hepatic steatosis on liver histology (odds ratio 3.25 for improvement) (Li 2024, PMID: 38579127). Insulin resistance (HOMA-IR) trended down but didn't reach statistical significance. The honest caveat, which the review's own authors state, is that these are enzyme and imaging markers, not confirmed outcomes like disease reversal, and the effect needs confirming in further research. For the full topic-by-topic evidence table, including this study's finer detail, see our does milk thistle work page.

The mushroom-poisoning story: a real drug, not a real supplement claim

The most dramatic number linked to silymarin is genuine, and it's the most misused. Intravenous silibinin, sold as the hospital drug Legalon SIL, has been used in nearly 1,500 documented cases of Amanita mushroom poisoning, with overall mortality under 10% versus more than 20% for older treatments like penicillin — though there are no controlled trials, for ethical reasons, only case series and uncontrolled treatment data (Mengs 2012, PMID: 22352731). That is a purified, high-dose intravenous infusion given in an ICU. An oral milk thistle capsule does not reproduce those blood levels and has never been shown to treat poisoning — if you or someone you know may have eaten a poisonous mushroom, that's an emergency room visit, not a supplement.

Where the liver claim falls apart: hepatitis C and alcoholic liver disease

Two of the conditions milk thistle is most often marketed for turn out to be its weakest evidence. In a 2012 JAMA trial (the SyNCH study), 154 people with chronic hepatitis C who had already failed interferon-based treatment were randomized to placebo or one of two silymarin doses — 420 mg or 700 mg three times daily, both well above the typical ~140 mg three-times-daily supplement dose — for 24 weeks. Only 2 participants per group met the primary liver-enzyme response target, ALT decline did not differ significantly between groups, and there was no difference in hepatitis C viral load (Fried 2012, PMID: 22797645). Higher-than-normal doses, not a lack of trying, and it still didn't beat placebo.

In alcoholic cirrhosis, a 200-patient, double-blind, multicenter trial randomized people to 450 mg/day silymarin or placebo and tracked time to death over two years. Twenty-nine of the 125 patients who completed the two-year follow-up died — 15 on silymarin, 14 on placebo — and the result held regardless of sex, continued drinking, or disease severity: silymarin had no significant effect on survival or disease course (Parés 1998, PMID: 9566830). A Cochrane review pooling 18 trials (1,088 patients) across both alcoholic and hepatitis B/C liver disease reached the same conclusion at the review level: no significant reduction in all-cause mortality (relative risk 0.78). A liver-related mortality benefit did show up when every trial was pooled, but it disappeared — relative risk 0.57, confidence interval crossing no effect — once the analysis was restricted to the minority of trials (28.6%) rated high quality (Rambaldi 2007, PMID: 17943794). Read the specific trials before the pooled headline: the two largest, best-designed studies in these exact conditions both came back null.

Why the results split this way: absorption, and the phosphatidylcholine fix

A likely reason milk thistle's benefits are inconsistent is that plain silymarin is poorly and unevenly absorbed orally. A human pharmacokinetic study comparing a silybin-phosphatidylcholine complex (IdB 1016, marketed as Siliphos or Realsil) against an equivalent dose of plain silymarin found the complex produced substantially higher blood silybin levels at every time point measured, and confirmed that complexation with phosphatidylcholine improves how much crosses the gut lining into circulation (Barzaghi 1990, PMID: 2088770). That's the actual scientific rationale behind "phytosome" or phosphatidylcholine-complex milk thistle products commanding a premium — and a reasonable factor in why some trials of plain silymarin underperform.

Layer inconsistent manufacturing on top of inconsistent absorption. Independent testing of 26 commercial milk thistle supplements from US and Czech markets found large differences in actual silymarin content, often at odds with what the label claimed, plus contamination with mycotoxins and pesticides across every product tested (Fenclova 2019, PMID: 31366891). Between a poorly absorbed active ingredient and a product category where the dose on the label isn't reliable, a trial finding a modest benefit and a bottle failing to reproduce it are not really in tension — see our label-trap breakdown for how to buy around this.

Standardization, drug interactions, and who should be cautious

A quality product is standardized to ~70–80% silymarin, so the practical buying signal is a printed silymarin percentage you can multiply against the extract weight — see our dosage guide for how to run that math. On drug interactions, the concern is smaller than early lab research suggested: a controlled crossover study giving 10 healthy adults silymarin alongside indinavir, an antiretroviral metabolized through the same CYP3A4/P-glycoprotein pathway researchers worried silymarin might block, found no significant change in indinavir blood levels (DiCenzo 2003, PMID: 12885100). That's one drug in a small trial, not a blanket clearance, so it's still worth telling a pharmacist you're taking it. Two cautions do hold up: milk thistle is in the ragweed family (Asteraceae), so people allergic to ragweed, daisies, or chrysanthemums may react to it (NCCIH; MedlinePlus), and because silymarin may modestly lower fasting glucose in people with type 2 diabetes (Voroneanu 2016, PMID: 27340676, rated low-quality evidence), anyone on antidiabetic medication should monitor and check with a clinician before stacking the two.

Milk thistle benefits at a glance

Does Milk Thistle Work? The Honest Evidence on Silymarin

What "the active" is, and why the dose is always silymarin

Milk thistle's studied effects trace to silymarin, a complex of flavonolignans whose main component is silibinin (silybin). Trials dose in silymarin milligrams, not seed milligrams — which is why the number that matters is almost never the big figure on the front of the bottle (see the label trap). Every result below only means something if you actually get a real silymarin dose, which most products don't disclose.

What the trials show — by outcome

Read together: the case is modest and specific — a reliable-ish reduction in elevated ALT/AST whose clinical meaning is debated, a low-quality glucose signal, and no confirmed survival benefit in cirrhosis. A narrative review of 29 RCTs is consistent, finding enzymes fell in about 65.5% of studies but without a pooled effect size (Calderon Martinez 2023). It's a mild adjunct, not a liver treatment — and no trial supports a "detox" or "cleanse" claim.

Safety and interactions

Milk thistle is generally well tolerated; the main reported side effects are mild gastrointestinal upset (loose stools, nausea). Two cautions are worth respecting:

Who it's most reasonable for

• People wanting a mild adjunct for elevated liver enzymes — e.g. NAFLD — alongside, not instead of, the diet, weight, and medical management that actually move the disease.
• People who'll get a real silymarin dose — a disclosed 80%-standardized extract at ~200 mg silymarin 2–3×/day, not an undisclosed "1,000 mg" softgel. See the dosage guide.
• Not a substitute for prescribed treatment of liver disease or diabetes, and not an antidote for mushroom or any acute poisoning.

Skip or get medical advice first if you: take antidiabetic drugs (possible additive lowering), have a ragweed-family allergy, or are pregnant or breastfeeding.

Milk Thistle Side Effects: GI Upset and Ragweed Allergy

Looking for a tested product? See our best milk thistle ranked by disclosed silymarin and cost, which also covers this safety detail →

The common effect: mild GI upset, and not much else

The side effect you're most likely to notice with milk thistle is gastrointestinal: loose stools, nausea, or bloating. A comprehensive review of the silymarin clinical literature, screening over 500 references down to 36 studies suitable for detailed analysis, found milk thistle has "a good safety record," with GI disturbances the most frequently reported adverse effect and allergic skin rash reported only occasionally (Saller 2001, PMID: 11735632). That's consistent with what shows up across the individual trials on our evidence page: adverse events in silymarin arms are generally comparable to placebo, and discontinuations for side effects are uncommon. There isn't a well-established dose-response relationship the way there is with some other GI-irritating botanicals — most people either tolerate it without issue or notice mild upset early on.

The allergy question: milk thistle is a ragweed relative

Ingested capsules and inhaled plant material are different exposure routes, and most people taking a milk thistle supplement aren't breathing in the ground plant the way an occupational or environmental exposure might involve. But the underlying allergen cross-reactivity is a real, family-level phenomenon, not a manufacturer's boilerplate warning. If you have a diagnosed ragweed, daisy, or related Asteraceae allergy, treat that as a real reason to check with a doctor before starting milk thistle, not a box to skip past.

Drug interactions: what the lab work suggested, and what human studies found

This is the safety question where precision matters most, because the two bodies of evidence point in different directions. In a test-tube study using human liver microsomes — isolated liver enzyme preparations, not a person — silybin and related silymarin compounds measurably inhibited several cytochrome P450 enzymes (Zuber 2002, PMID: 12410543). Findings like that are exactly why milk thistle carries a drug-interaction caution on paper, and if you stopped reading there, you'd reasonably worry it behaves like berberine or St. John's wort.

But when the same question was tested in actual people taking milk thistle, the picture looked different. Researchers gave healthy volunteers a standardized milk thistle product for 14 days, then measured its effect on midazolam, a drug used specifically as a marker of CYP3A4 enzyme activity, alongside rifampin and clarithromycin as positive controls known to strongly induce or inhibit that enzyme. Rifampin increased midazolam clearance more than 20-fold and clarithromycin decreased it by 88% — both drugs behaved exactly as expected — while milk thistle produced no significant change in midazolam's pharmacokinetics, leading the authors to conclude it has no clinically relevant effect on CYP3A activity in vivo (Gurley 2006, PMID: 16432272). A separate trial from the same research group found milk thistle supplementation didn't meaningfully change digoxin levels, a standard marker for P-glycoprotein, another transporter milk thistle was flagged for inhibiting in the lab (Gurley 2006, PMID: 16221754). And in HIV-positive and healthy volunteers, coadministering milk thistle with indinavir — a protease inhibitor metabolized through the same CYP3A4/P-glycoprotein pathway — produced no significant change in indinavir blood levels (DiCenzo 2003, PMID: 12885100).

Three separate human trials, three different drugs, the same result: no clinically meaningful interaction. That's a real, tested pattern, not a hand-wave dismissal of the in-vitro data — but it's a pattern across the specific drugs studied, not proof for every CYP3A4 or P-glycoprotein substrate. If you take a medication with a narrow safe-dose range, especially one metabolized the same way, tell your doctor or pharmacist you're taking milk thistle rather than assuming the human data automatically covers your specific drug.

Two more cautions: blood sugar and a theoretical estrogen effect

Silymarin may modestly lower fasting glucose. A meta-analysis of five small randomized trials in people with type 2 diabetes found reductions in fasting glucose and HbA1c, though the authors rated the underlying evidence low quality (Voroneanu 2016, PMID: 27340676). If that effect is real, it would add to the glucose-lowering effect of insulin or oral diabetes medication, so anyone on those drugs should monitor blood sugar and loop in a clinician rather than adding milk thistle on their own.

Separately, an animal study found silymarin acts as a selective estrogen receptor beta agonist, producing estrogen-like effects in bone in ovariectomized rats while having no estrogenic (or even mildly anti-estrogenic) effect in the uterus of the same animals (Seidlóvá-Wuttke 2003, PMID: 14568570). That's receptor-binding and rodent data, not a human safety trial, and it doesn't mean milk thistle behaves like a hormone in people. But it's the actual research basis for the standard caution against milk thistle in pregnancy, breastfeeding, and hormone-sensitive conditions such as breast, uterine, or ovarian cancer — a theoretical concern grounded in a real finding, stated as exactly that.

Milk thistle side effects at a glance